$204 Million is the total value of Foresite Capital Management II, LLC's 20 reported holdings in Q1 2016. The portfolio turnover from Q4 2015 to Q1 2016 was 16.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AIMT | Aimmune Therapeutics, Inc. | $55,432,000 | -26.5% | 4,087,900 | 0.0% | 27.13% | +7.3% | |
| UAM | Universal American Corp. | $20,098,000 | +2.0% | 2,814,883 | 0.0% | 9.84% | +48.9% | |
| ADRO | Sell | Aduro Biotech, Inc. | $16,947,000 | -63.7% | 1,322,916 | -20.2% | 8.29% | -46.9% |
| EPZM | Buy | Epizyme, Inc. | $14,447,000 | -22.2% | 1,191,995 | +2.8% | 7.07% | +13.5% |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $14,322,000 | -32.6% | 1,761,567 | 0.0% | 7.01% | -1.6% | |
| RGLS | Buy | Regulus Therapeutics Inc. | $14,130,000 | -7.4% | 2,038,939 | +16.5% | 6.92% | +35.1% |
| ALDR | Buy | Alder Biopharmaceuticals Inc. | $12,990,000 | -6.4% | 530,416 | +26.3% | 6.36% | +36.7% |
| AERI | Buy | Aerie Pharmaceuticals, Inc. | $11,544,000 | -35.8% | 949,372 | +28.6% | 5.65% | -6.3% |
| NSTG | Buy | NanoString Technologies, Inc. | $10,037,000 | +39.4% | 659,486 | +34.7% | 4.91% | +103.5% |
| ZFGN | Sell | Zafgen, Inc. | $9,501,000 | +1.5% | 1,422,273 | -4.4% | 4.65% | +48.1% |
| XLRN | Buy | Acceleron Pharma Inc. | $4,594,000 | -31.5% | 174,089 | +26.6% | 2.25% | +0.0% |
| ARDX | Sell | Ardelyx, Inc. | $3,639,000 | -58.0% | 468,297 | -2.1% | 1.78% | -38.7% |
| OREX | Buy | Orexigen Therapeutics, Inc. | $3,636,000 | -66.0% | 6,462,080 | +3.8% | 1.78% | -50.4% |
| NVET | Buy | Nexvet Biopharma public limited company | $2,930,000 | -1.7% | 887,801 | +1.6% | 1.43% | +43.5% |
| BDSI | Sell | BioDelivery Sciences International, Inc. | $2,401,000 | -47.1% | 743,395 | -21.6% | 1.18% | -22.8% |
| ANAC | Anacor Pharmaceuticals, Inc.put | $1,996,000 | -43.0% | 31,000 | 0.0% | 0.98% | -16.8% | |
| RGNX | Regenxbio Inc. | $1,693,000 | -34.9% | 156,741 | 0.0% | 0.83% | -4.9% | |
| Buy | NeuroDerm Ltd. | $1,691,000 | +77.8% | 119,781 | +114.7% | 0.83% | +159.6% | |
| SCYX | SCYNEXIS, Inc. | $1,359,000 | -35.1% | 337,177 | 0.0% | 0.66% | -5.3% | |
| BDSI | Sell | BioDelivery Sciences International, Inc.put | $943,000 | -6.3% | 209,500 | -0.2% | 0.46% | +37.1% |
| AXGT | Exit | Axovant Sciences Ltd. | $0 | – | -65,000 | -100.0% | -0.39% | – |
| BDSI | Exit | BioDelivery Sciences International, Inc.call | $0 | – | -310,000 | -100.0% | -0.50% | – |
| QTNT | Exit | Quotient Limited | $0 | – | -192,158 | -100.0% | -1.03% | – |
| ANAC | Exit | Anacor Pharmaceuticals, Inc.call | $0 | – | -31,000 | -100.0% | -1.17% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-05-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Epizyme, Inc. | 29 | Q4 2021 | 11.9% |
| Acceleron Pharma Inc. | 24 | Q3 2021 | 4.8% |
| Aerie Pharmaceuticals, Inc. | 22 | Q1 2020 | 40.3% |
| 10x Genomics, Inc. | 17 | Q3 2023 | 100.0% |
| Aimmune Therapeutics, Inc. | 17 | Q3 2019 | 41.0% |
| Alder BioPharmaceuticals, Inc. | 16 | Q3 2019 | 12.6% |
| Zafgen, Inc. | 12 | Q3 2017 | 33.5% |
| BioDelivery Sciences International, Inc. | 12 | Q1 2019 | 3.2% |
| Insmed Incorporated | 11 | Q1 2020 | 13.8% |
| Adaptimmune Therapeutics PLC | 9 | Q4 2018 | 11.3% |
View Foresite Capital Management II, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-16 |
View Foresite Capital Management II, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.